Phenotypic Variations of Mild-to-Moderate Obstructive Pulmonary Diseases According to Airway Inflammation and Clinical Features

References

• Welte T, Groneberg DA. Asthma and COPD. Exp Toxicol Pathol. 2006;57(Suppl 2):35–40. doi:10.1016/j.etp.2006.02.004
   PubMedGoogle Scholar
• Wenzel SE. Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 Immunity and Beyond. Am J Respir Cell Mol Biol. 2016;55:1–4. doi:10.1165/rcmb.2016-0141PS
   PubMed Web of Science ®Google Scholar
• Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530–534. doi:10.1164/ajrccm.153.2.8564092
   PubMed Web of Science ®Google Scholar
• Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med. 2000;162:1355–1360. doi:10.1164/ajrccm.162.4.9910097
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120. doi:10.1136/thorax.55.2.114
   PubMed Web of Science ®Google Scholar
• Dunn RM, Busse PJ, Wechsler ME. Asthma in the elderly and late-onset adult asthma. Allergy. 2018;73:284–294. doi:10.1111/all.13258
   PubMed Web of Science ®Google Scholar
• Nyenhuis SM, Schwantes EA, Evans MD, Mathur SK. Airway neutrophil inflammatory phenotype in older subjects with asthma. J Allergy Clin Immunol. 2010;125:1163–1165. doi:10.1016/j.jaci.2010.02.015
   PubMed Web of Science ®Google Scholar
• Ho J, He W, Chan MTV, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Sci Rep. 2017;7:13451. doi:10.1038/s41598-017-13745-x
   PubMed Web of Science ®Google Scholar
• Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356:1313–1317. doi:10.1016/S0140-6736(00)02815-4
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–735. doi:10.1136/thx.2008.108027
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419. doi:10.1183/13993003.01359-2015
   PubMed Web of Science ®Google Scholar
• Garth J, Barnes JW, Krick S. Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. Int J Mol Sci. 2018;19:19. doi:10.3390/ijms19113402
   Web of Science ®Google Scholar
• Howard R, Rattray M, Prosperi M, Custovic A. Distinguishing asthma phenotypes using machine learning approaches. Curr Allergy Asthma Rep. 2015;15:38. doi:10.1007/s11882-015-0542-0
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Massaro S, Fakhimi M, Stergioulas L, Price D. COPD phenotypes and machine learning cluster analysis: a systematic review and future research agenda. Respir Med. 2020;171:106093. doi:10.1016/j.rmed.2020.106093
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma. Global strategy for asthma management and prevention; 2015. Available from: www.ginasthma.org. Accessed June 18, 2021.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; ( updated 2015). Available from: www.goldcopd.org. Accessed June 18, 2021.
   Google Scholar
• Brusasco V, Crapo R, Viegi G; American Thoracic Society, European Respiratory Society. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J. 2005;26:1–2. doi:10.1183/09031936.05.00034205
   PubMed Web of Science ®Google Scholar
• Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing—1999. Am J Respir Crit Care Med. 2000;161:309–329. doi:10.1164/ajrccm.161.1.ats11-99
   PubMed Web of Science ®Google Scholar
• Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med. 2000;161:475–478. doi:10.1164/ajrccm.161.2.9903097
   PubMed Web of Science ®Google Scholar
• Lindberg A, Bjerg A, Bjerg-Bäcklund A, Rönmark E, Larsson L-G, Lundbäck B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking report from the obstructive lung disease in northern Sweden studies. Respir Med. 2006;100:264–272. doi:10.1016/j.rmed.2005.04.029
   PubMed Web of Science ®Google Scholar
• Fahy JV. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol. 2015;15:57–65. doi:10.1038/nri3786
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395. doi:10.1164/rccm.200903-0392OC
   PubMed Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098. doi:10.1056/NEJMoa1106469
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187:875–883. doi:10.1084/jem.187.6.875
   PubMed Web of Science ®Google Scholar
• Gauthier M, Chakraborty K, Oriss TB, et al. Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. JCI Insight. 2017;2(13):e94580. doi:10.1172/jci.insight.94580
   Web of Science ®Google Scholar
• Howarth P, Babu K, Arshad H, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005;60:1012–1018. doi:10.1136/thx.2005.045260
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354:697–708. doi:10.1056/NEJMoa050580
   PubMed Web of Science ®Google Scholar
• Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity. Trends Immunol. 2017;38:942–954. doi:10.1016/j.it.2017.07.003
   PubMed Web of Science ®Google Scholar
• Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res. 1991;17:17–23. doi:10.3109/01902149109063278
   PubMed Web of Science ®Google Scholar
• Kim Y-M, Kim H, Lee S. et al. Airway G-CSF identifies neutrophilic inflammation and contributes to asthma progression. Eur Respir J.2020;55(2):1900827. doi:10.1183/13993003.00827-2019
   Web of Science ®Google Scholar
• Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281–1290. doi:10.7150/ijbs.4874
   PubMed Web of Science ®Google Scholar
• Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest. 2002;122:1543–1552. doi:10.1378/chest.122.5.1543
   PubMed Web of Science ®Google Scholar
• Barbaro MPF, Spanevello A, Palladino GP, Salerno FG, Lacedonia D, Carpagnano GE. Exhaled matrix metalloproteinase-9 (MMP-9) in different biological phenotypes of asthma. Eur J Intern Med. 2014;25:92–96. doi:10.1016/j.ejim.2013.08.705
   PubMed Web of Science ®Google Scholar
• Koga H, Miyahara N, Fuchimoto Y, et al. Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses. Respir Res. 2013;14:8. doi:10.1186/1465-9921-14-8
   PubMed Web of Science ®Google Scholar
• Malyak M, Smith MF, Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. J Immunol. 1998;161:2004–2010.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020;55(3):1901509. doi:10.1183/13993003.01509-2019
   Google Scholar
• Hiles SA, Gibson PG, Agusti A, McDonald VM. Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract. 2020;9:1255–1264.e2. doi:10.1016/j.jaip.2020.09.046
   PubMed Web of Science ®Google Scholar
• Cowan DC, Cowan JO, Palmay R, Williamson A, Taylor DR. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax. 2010;65:384–390. doi:10.1136/thx.2009.126722
   PubMed Web of Science ®Google Scholar
• Ghebre MA, Pang PH, Diver S, et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol. 2018;141:2027–2036.e12. doi:10.1016/j.jaci.2018.04.013
   PubMed Web of Science ®Google Scholar
• Górska K, Paplińska-Goryca M, Nejman-Gryz P, Goryca K, Krenke R. Eosinophilic and neutrophilic airway inflammation in the phenotyping of mild-to-moderate asthma and chronic obstructive pulmonary disease. COPD. 2017;14:181–189. doi:10.1080/15412555.2016.1260539
   PubMedGoogle Scholar
• Diver S, Richardson M, Haldar K, et al. Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus-predominant subgroup. Allergy. 2020;75:808–817. doi:10.1111/all.14058
   PubMed Web of Science ®Google Scholar
• Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J. 2009;34:812–818. doi:10.1183/09031936.00174408
   PubMed Web of Science ®Google Scholar